In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniae were tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 microgram/ml (range, 0.015 to 2 micrograms/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 microgram/ml) than older strains that had been passaged more extensively.
Roblin
P M
PM
Department of Pediatrics, SUNY Health Science Center at Brooklyn, New York 11203, USA.
Hammerschlag
M R
MR
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D015575:Roxithromycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; D015575:Roxithromycin; D004917:Erythromycin; D017963:Azithromycin; C106791:telithromycin